Tumour-associated immune responses and isolated carcinoembryonic antigen and alpha feto-protein levels related to survival in ovarian cancer patients.
The presence of a tumour-associated immune response in 37 patients with ovarian cancer as assessed by blastogenesis (lymphocyte transformation) evoked by ovarian cancer cell extracts, has been correlated with survival following the test. The difference in these responses is unlikely to be accounted for on the basis of general impairment of cell-mediated immuno-competence. Serum carcinoembryonic antigen (CEA) was also determined in 27 ovarian cancer patients to assess its prognostic significance. Raised CEA levels and absence of blastogenic response to tumour cell extract during relapse are associated with a worse prognosis but neither of these parameters are significant in remission. Possible applications of these findings to the clinical management of ovarian cancer patients are discussed. Serum alpha feto-protein levels measured by radioimmunoassay were not found to be raised in any of the 32 ovarian cancer patients in whom it was measured.
D000368:Aged; D002272:Carcinoembryonic Antigen / Q000032:analysis*; D003537:Cystadenoma / Q000276:immunology; D005260:Female; D005326:Fetal Proteins / Q000032:analysis*; D006801:Humans; D007111:Immunity, Cellular; D008213:Lymphocyte Activation; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000276:immunology* / Q000401:mortality; D011379:Prognosis; D000509:alpha-Fetoproteins / Q000032:analysis*
D002272:Carcinoembryonic Antigen; D005326:Fetal Proteins; D000509:alpha-Fetoproteins